infectious diseases
To sponsor this category, click here | subscribe to this category RSS

Home » Archives for infectious diseases

XMRV? Or Umpteen Other Viruses? Or What?

Tuesday, August 24th, 2010

The long-delayed PNAS paper on the chronic fatigue/XMRV results has finally come out .

Read the full story

Know How to Make Praziquantel? Tell The World.

Tuesday, August 3rd, 2010

One of the people I met this past weekend was Matt Todd, chemistry professor at the University of Sydney. We talked about a project his lab is working on, and I wanted to help call attention to it

Read the full story

Unlovely Polyphenols

Monday, May 10th, 2010

Here’s a new paper from the folks at the Burnham Institute and UCSD on a new target for vaccinia virus. They’re going after a virulence factor (N1L) through computational screening, which is a challenge, since this is a protein-protein interaction.

Read the full story

Dundee’s NMT Inhibitors for Sleeping Sickeness: An Update

Friday, April 9th, 2010

I’ve had some follow-up with the people at Dundee who reported those compounds for sleeping sickness recently. As mentioned, one of the key points in making these a viable therapy will be brain penetration, since trypanosomes in the central nervous system are a hallmark of the most serious phase of the disease. The group has a patent application out ( WO2010026365 ), and you can see from it that they’ve been addressing this problem

Read the full story

Good News Versus Sleeping Sickness

Thursday, April 1st, 2010

Nature has a very encouraging paper out today on some potential treatments for trypanosomiasis (sleeping sickness). The mechanism is protein N-myristoylation (catalyzed by an enzyme abbreviated as NMT) which is a process that’s important for membrane targeting and trafficking. NMT has been shown to be essential for trypanosome survival by siRNA experiments, so it’s a pretty well-validated target

Read the full story

Chronic Fatigue – Retroviruses to Blame, or Not?

Tuesday, October 13th, 2009

Chronic fatigue syndrome has long been controversial and mysterious. Is the mystery clearing up, or getting deeper?

Read the full story
No Image

Altermune – Real Stuff or Not?

Friday, May 8th, 2009

Kary Mullis is an outlier among Nobel Prize winners.

Read the full story

Angiogenesis Inhibitors: Helping or Hurting?

Thursday, May 7th, 2009

Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse?

Read the full story

Into the Clinic. And Right Back Out.

Wednesday, May 6th, 2009

Here’s a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies. A company called SGX, recently acquired by Eli Lilly, has been developing a kinase inhibitor (SGX523) targeting the enzyme cMET.

Read the full story

Farewell to ACAT, and to Lots of Time and Money, Too

Tuesday, May 5th, 2009

Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had already been a drug target for some years before I first heard about it, and has remained one.

Read the full story